Regulatory B Cells Contribute to the Impaired Antitumor Immunity in Ovarian Cancer Patients

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Dec 7

PMID 26638169

Citations 61

Authors

Xin Wei

Yangqiu Jin

Yinpu Tian

Huiyuan Zhang

Jie Wu

Wei Lu

Xiaofen Lu

Affiliations

Soon will be listed here.

Abstract

Multiple factors in the tumor microenvironment were found to inhibit antitumor adaptive immune responses, allowing tumor persistence and growth. In this study, ascites from ovarian cancer patients were collected. We observed that a population of interleukin-10(+) B (IL-10(+) B) cells was preferentially enriched in the ascites. This population was associated with naive B cell phenotype or IgM or class-switched memory B cell phenotypes. The frequencies of IL-10(+) B cells were negatively correlated with the frequencies of interferon gamma-producing (IFN-g(+)) CD8(+) T cells and were positively correlated with the frequencies of Foxp3(+) CD4(+) T cells. To examine whether increased IL-10(+) B cells in ascites could directly result in increased suppression of IFN-g production by CD8(+) T cells, we cocultured CD8(+) T cells with autologous blood B cells or ascitic B cells and found that CD8(+) T cells cocultured with ascitic B cells demonstrated significantly suppressed IFN-g production. This suppression was in part mediated by IL-10 as well as low CD80/CD86 expression, since depletion of IL-10 and stimulation of CD28 partially reverted IL-10(+) B cell-mediated suppression. Together, these data demonstrated an additional regulatory mechanism in the tumor microenvironment, which utilizes IL-10(+) B cells.

Citing Articles

A Comprehensive Methodology for Immortalizing Tumor-Infiltrating B Lymphocytes from Epithelial Cancers.

Tamuli B, Biswas S Methods Mol Biol. 2025; 2909:245-256.

PMID: 40029526 DOI: 10.1007/978-1-0716-4442-3_16.

Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments.

Gupta R, Kumar R, Penn C, Wajapeyee N Trends Immunol. 2025; 46(2):166-181.

PMID: 39855990 PMC: 11835538. DOI: 10.1016/j.it.2024.12.006.

B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications.

Wu X, Huang Q, Chen X, Zhang B, Liang J, Zhang B Theranostics. 2025; 15(2):605-631.

PMID: 39744696 PMC: 11671382. DOI: 10.7150/thno.105423.

The CD40/CD40L Pathway Regulates the Aggressiveness of Ovarian Cancer Cells via the Activation of Regulatory B Cells.

Ma S, Chen P, Guo S, Wang L, Hu J, Shao J Biochem Genet. 2024; .

PMID: 39576490 DOI: 10.1007/s10528-024-10945-9.

Tertiary Lymphoid Structures in Microorganism-Related Cancer.

Deng S, Yang X, He L, Hou Y, Meng H Cancers (Basel). 2024; 16(20).

PMID: 39456558 PMC: 11505735. DOI: 10.3390/cancers16203464.

References

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

Brichard V, Lejeune D . GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine. 2007; 25 Suppl 2:B61-71. DOI: 10.1016/j.vaccine.2007.06.038. View

Blair P, Norena L, Flores-Borja F, Rawlings D, Isenberg D, Ehrenstein M . CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010; 32(1):129-40. DOI: 10.1016/j.immuni.2009.11.009. View

Sayi A, Kohler E, Toller I, Flavell R, Muller W, Roers A . TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol. 2010; 186(2):878-90. DOI: 10.4049/jimmunol.1002269. View

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B . A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038):1643-7. DOI: 10.1126/science.1840703. View

Nelson B . CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010; 185(9):4977-82. DOI: 10.4049/jimmunol.1001323. View

Sims G, Ettinger R, Shirota Y, Yarboro C, Illei G, Lipsky P . Identification and characterization of circulating human transitional B cells. Blood. 2005; 105(11):4390-8. PMC: 1895038. DOI: 10.1182/blood-2004-11-4284. View

Hagemann T, Wilson J, Burke F, Kulbe H, Li N, Pluddemann A . Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006; 176(8):5023-32. DOI: 10.4049/jimmunol.176.8.5023. View

Nishikawa H, Jager E, Ritter G, Old L, Gnjatic S . CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 2005; 106(3):1008-11. DOI: 10.1182/blood-2005-02-0607. View

10.

Liu J, Zhan W, Kim C, Clayton K, Zhao H, Lee E . IL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses. PLoS One. 2014; 9(2):e89236. PMC: 3931714. DOI: 10.1371/journal.pone.0089236. View

11.

Noy R, Pollard J . Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41(1):49-61. PMC: 4137410. DOI: 10.1016/j.immuni.2014.06.010. View

12.

Lemoine S, Morva A, Youinou P, Jamin C . Human T cells induce their own regulation through activation of B cells. J Autoimmun. 2011; 36(3-4):228-38. DOI: 10.1016/j.jaut.2011.01.005. View

13.

Topalian S, Hom S, Kawakami Y, Mancini M, Schwartzentruber D, Zakut R . Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes. J Immunother (1991). 1992; 12(3):203-6. DOI: 10.1097/00002371-199210000-00013. View

14.

Olkhanud P, Damdinsuren B, Bodogai M, Gress R, Sen R, Wejksza K . Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 2011; 71(10):3505-15. PMC: 3096701. DOI: 10.1158/0008-5472.CAN-10-4316. View

15.

Das A, Ellis G, Pallant C, Lopes A, Khanna P, Peppa D . IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 2012; 189(8):3925-35. PMC: 3480715. DOI: 10.4049/jimmunol.1103139. View

16.

Nelson B . The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008; 222:101-16. DOI: 10.1111/j.1600-065X.2008.00614.x. View

17.

Geffroy-Luseau A, Chiron D, Descamps G, Jego G, Amiot M, Pellat-Deceunynck C . TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. Front Immunol. 2012; 2:83. PMC: 3342082. DOI: 10.3389/fimmu.2011.00083. View

18.

Siewe B, Stapleton J, Martinson J, Keshavarzian A, Kazmi N, Demarais P . Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro. J Leukoc Biol. 2013; 93(5):811-8. PMC: 3629440. DOI: 10.1189/jlb.0912436. View

19.

Zhang X . Regulatory functions of innate-like B cells. Cell Mol Immunol. 2013; 10(2):113-21. PMC: 4003048. DOI: 10.1038/cmi.2012.63. View

20.

Nielsen J, Sahota R, Milne K, Kost S, Nesslinger N, Watson P . CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012; 18(12):3281-92. DOI: 10.1158/1078-0432.CCR-12-0234. View